In summary, our study demonstrates that no XMRV/PMLV
assay in any of the nine participating laboratories could
reproducibly detect XMRV/P-MLV in fifteen subjects
(fourteen with CFS) who had previously been reported as
XMRV/P-MLV-infected usually at multiple time points and
Downloaded from
www.sciencemag.org on September 28, 2011
/
www.sciencexpress.org / 22 September 2011 / Page 4 / 10.1126/science.1213841
often by multiple assays (2, 4). The two laboratories (WPI
and NCI/Ruscetti labs) that reported positive results in this
study reported similar rates of reactivity among XMRV/PMLV
subjects and known negative control donor samples.
The results from both laboratories were inconsistent when
their assays were performed in parallel on replicate sample
aliquots derived from individual subject specimens. There
was also no agreement of reactivity when comparing results
between these two laboratories for the 30 blinded XMRV/PMLV
cohorts and control samples. In contrast, assays
developed by FDA (Lo and Hewlett), CDC, NCI/DRP,
Abbott Diagnostics, Abbott Molecular and Gen-Probe, all of
which have been designed to detect XMRV and relevant
MLVs with high sensitivity and specificity, failed to detect
evidence of viral infection in any of the previously positive
subjects, including CFS patients, or negative control
specimens represented in the study.